Myrexis, Inc. focuses on identifying, evaluating, and making financial investments in life sciences assets. The company was formerly known as Myriad Pharmaceuticals, Inc. and changed its name to Myrexis, Inc. in July 2010. Myrexis, Inc. is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:MYRX
CUSIPN/A
Phone801-214-7800
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding Shares34,480,000
Myrexis (OTCMKTS:MYRX) Frequently Asked Questions
What is Myrexis' stock symbol?
Myrexis trades on the OTCMKTS under the ticker symbol "MYRX."
Who are some of Myrexis' key competitors?
Some companies that are related to Myrexis include Cotinga Pharmaceuticals (COTQF), Biostar Pharmaceuticals (BSPM), Immune Pharmaceuticals (IMNP), Bioblast Pharma (ORPN), Praxsyn (PXYN), Auris Medical (EARS), Respirerx Pharmaceuticals (RSPI), Orexigen Therapeutics (OREX), Integrated BioPharma (INBP), GlobeImmune (GBIM), Aoxing Pharmaceutical (AOXG), American Bio Medica (ABMC), Generex Biotechnology (GNBT), Capstone Therapeutics Corp Common Stock (CAPS) and Rosetta Genomics (ROSG).
Who are Myrexis' key executives?
Myrexis' management team includes the folowing people:
- Mr. Jonathan M. Couchman CFA, Chairman, CEO, Pres, CFO and Principal Accounting Officer (Age 48)
Has Myrexis been receiving favorable news coverage?
Press coverage about MYRX stock has trended somewhat positive on Sunday, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Myrexis earned a coverage optimism score of 0.10 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 47.79 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
How do I buy shares of Myrexis?
Shares of MYRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Myrexis' stock price today?
One share of MYRX stock can currently be purchased for approximately $0.0454.
How big of a company is Myrexis?
Myrexis has a market capitalization of $1.57 million.
How can I contact Myrexis?
Myrexis' mailing address is C/O XSTELOS HOLDINGS INC. 630 FIFTH AVENUE SUITE 2260, NEW YORK NY, 10020. The biopharmaceutical company can be reached via phone at 801-214-7800 or via email at [email protected]
MarketBeat Community Rating for Myrexis (MYRX)
MarketBeat's community ratings are surveys of what our community members think about Myrexis and other stocks. Vote "Outperform" if you believe MYRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
